Search Results65 results found
CSL Behring conducts clinical trials for breakthrough medicines that treat hemophilia and other rare diseases. See our current clinical trials.
CSL Behring's clinical trial subjects are entitled to specific rights. A clinical trial investigation must comply with a specific plan or protocol. Learn more.
CSL Behring's clinical trials are designed to test the efficacy of our latest breakthrough medicines. Find out how you can participate.
CSL Behring can provide you with a number of questions to ask the study investigator or coordinator before enrolling in a study. Learn more.
OF OUR PRODUCTS 28 3.1 Bioethics 30 3.1.1 Research and development 30 3.1.2 Clinical trials 30 3.1.3 Stem cell research 31 3.1.4 Animal welfare 31 3.2 Adverse events 32 3.3
CSL Behring's clinical trials are carefully supervised, monitored, and documented in accordance with regulatory authorities. Learn more about how we conduct our research.
FDA approval of flexible dosing for Hizentra is based on pharmacometrics (modeling and simulation). Clinical trials using these alternative Hizentra dosing regimens were not
CSL Behring conducts clinical trials to ensure our products are safe and effective for our patients. Learn about our current clinical trials and breakthrough medicines.
attack has been shown to provide significantly faster relief to a patient (median onset of relief of 48 minutes in clinical trials, versus more than four hours in placebo group).
The most common adverse reactions in clinical trials were injection site reactions and headache. Data from PROLONG- 9FP were recently published in the American Society of